Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Sold this over a week back at a 15 per cent loss. You are right 2017 sp for 2019 profits but pe is partly based on momentum. This has lost momentum because of covid, though its doing well under the circumstances. It could drift a bit lower still at which point it could then be an excellent buy. Already a buy if you are prepared to sit the covid stagnancy out - results not next year but year after will probably pick up a lot and then we can be on a path to returning up to old higher sp.
Nice to see-
'We have experienced strong sales momentum in Q1 ' In the final results.
The sp has dropped to the levels of 2017 but earnings and profits should be more in line with those of last year when the sp was 25% + higher. Seems a good entry point so I'm in.
Yesterday on motley fool hidden winners subscription service.
Good to see the CEO is buying too...
Keith Neilson, CEO, purchased 7,710 ordinary shares of 1p each at a price of 1,740 pence per Ordinary Share. Mr Neilson also exercised options over 13,383 Ordinary Shares
Bought in today at 1,720 as I like their healthy cash position, business model, growth prospects and that a major proportion of their revenue is visible upfront from repeat subscriptions. I note that they have just abandoned a placing as they lost out on their planned acquisition of Vitalware. That's a setback, but I think this is a good entry point for a medium term hold. Stop loss 1500, looking for an exit point at 2,000.
Decent update ysday, but muted reaction, do we have any watchers or takers here at current price? I see Paul Scott covered it although didn’t see the write up as not a premium member, usually a good sign if he likes it, from a balance sheet perspective
'10% growth in adjusted EBITDA ' - unfortunately my model says the high P/E ratio might now being questioned. A valuable cash producing company nonetheless.
Expect a sharp uptick today
Very encouraging comments in Telegraph today
Deal in the making
but nobody seems to know why
imv
Craneware: Numis cuts target price from 405p to 390p reiterating a hold recommendation. Investec reduces target price from 410p to 365p, while upgrading from hold to buy.
26 June 2013 - Craneware (AIM: CRW.L), the market leader in automated revenue integrity solutions for the US healthcare market, provides an update on trading for the year ending 30 June 2013. The Group continues to see increased levels of sales activity and conversion of its growing sales pipeline into revenue in our underlying small and medium sized hospital business. Progress also continues to be made with a significant number of large sales opportunities. It has not, however, been possible to sign one of these large deals in this period due mainly to corporate activity within this customer base. Management expects that the likelihood of one of these deals closing before the end of the financial year is now low. In the past, at least one of these large sales deals has contributed to revenue growth in any individual year, as was the case in 2012. As such, without the contribution from new large deals and with the final month of the financial year still to complete, the Board expects to report revenue for the year in a range of $41 million to $42 million and adjusted EBITDA in a range of $11.9 million to $12.6 million, both in line or marginally ahead of the prior year but below current market expectations. Our historical success in large hospital networks and other 'routes to market' confirms the demand for our product set in this significant sector of the market. However, these sales are more complex and involve a much longer sales cycle which is inevitably harder to predict, particularly when further complicated by current high levels of corporate activity in this segment. The investment we made during the year in our sales force has produced the expected positive results in our underlying small and medium sized business. Looking forward, the Company will be dedicating more resources on large hospital networks and other routes to market to specifically focus on delivering revenue growth from these sectors on a more predictable basis. Keith Neilson, CEO of Craneware,commented, "The success we have seen in our investment in sales is not fully reflected in these results due to the large deals we have in the pipeline not closing during this year. Although we believe we have been hampered in our efforts to close these deals by corporate activity within our customer base, this trend of consolidation will not ease. We will therefore continue to build our focused team dedicated to servicing these organisations which we believe will provide us with better predictability and ultimately a greater success in closing these deals in the future. Fiscal and regulatory pressures on all US hospitals continues to drive interest in our unique suite of solutions and we are confident in the ongoing strength and relevance of our position within the US healthcare market."
in down market
that's my girl
its building a nice support base here at £4 don't think it will sit here too much longer
just can't find any problem with that profits starting to increase and good growth prospects dividend too gl chaps
u knew the disgruntled/impatient were lurking...
..
..
& still grounded scratch scratch scratch